文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Ban T A, Morey L C, Fjetland O K, Rengo F, Ferrara N, Agnetti V, D'Onofrio M, Facchini G, Anzivino F, Perego M A

Department of Psychiatry, Vanderbilt University, Nashville, TN.

Prog Neuropsychopharmacol Biol Psychiatry. 1992 Sep;16(5):661-76. doi: 10.1016/0278-5846(92)90023-8.

In a multicenter, placebo-controlled, double-blind clinical trial in 156 elderly patients with psychopathologic symptoms, glycosaminoglycan polysulfate was found to be a therapeutically effective agent in the treatment of the earliest manifestations of a dementing process. 2. Treatment with glycosaminoglycan polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 24 weeks, was significantly superior to an inactive placebo on several outcome measures including the SCAG Total and factor scores (i.e., Cognitive Dysfunction, Withdrawal, Agitation/Irritability and Depression), the NOWLIS Total and Fatiguability factor scores, the MMSE, the HAM-D Total and Vegetative Symptoms factor score and the CGI Severity of Illness and Global Improvement. 3. The drug was well tolerated; vital signs and laboratory measures did not show clinically significant changes within the experimental period.

在一项针对156名有精神病理症状的老年患者的多中心、安慰剂对照、双盲临床试验中，发现多硫酸糖胺聚糖是治疗痴呆过程最早表现的一种有效治疗药物。2. 以600 LRU的日剂量多硫酸糖胺聚糖进行治疗，基于分剂量方案给药24周，在包括SCAG总分及因子评分（即认知功能障碍、退缩、激越/易怒和抑郁）、NOWLIS总分及易疲劳因子评分、MMSE、HAM-D总分及躯体症状因子评分以及CGI疾病严重程度和总体改善情况等多项结局指标上，显著优于无活性的安慰剂。3. 该药物耐受性良好；在实验期间生命体征和实验室指标未显示出具有临床意义的变化。

Ban T A, Morey L C, Fjetland O K, Rengo F, Ferrara N, Agnetti V, D'Onofrio M, Facchini G, Anzivino F, Perego M A

Department of Psychiatry, Vanderbilt University, Nashville, TN.

Prog Neuropsychopharmacol Biol Psychiatry. 1992 Sep;16(5):661-76. doi: 10.1016/0278-5846(92)90023-8.

In a multicenter, placebo-controlled, double-blind clinical trial in 156 elderly patients with psychopathologic symptoms, glycosaminoglycan polysulfate was found to be a therapeutically effective agent in the treatment of the earliest manifestations of a dementing process. 2. Treatment with glycosaminoglycan polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 24 weeks, was significantly superior to an inactive placebo on several outcome measures including the SCAG Total and factor scores (i.e., Cognitive Dysfunction, Withdrawal, Agitation/Irritability and Depression), the NOWLIS Total and Fatiguability factor scores, the MMSE, the HAM-D Total and Vegetative Symptoms factor score and the CGI Severity of Illness and Global Improvement. 3. The drug was well tolerated; vital signs and laboratory measures did not show clinically significant changes within the experimental period.

在一项针对156名有精神病理症状的老年患者的多中心、安慰剂对照、双盲临床试验中，发现多硫酸糖胺聚糖是治疗痴呆过程最早表现的一种有效治疗药物。2. 以600 LRU的日剂量多硫酸糖胺聚糖进行治疗，基于分剂量方案给药24周，在包括SCAG总分及因子评分（即认知功能障碍、退缩、激越/易怒和抑郁）、NOWLIS总分及易疲劳因子评分、MMSE、HAM-D总分及躯体症状因子评分以及CGI疾病严重程度和总体改善情况等多项结局指标上，显著优于无活性的安慰剂。3. 该药物耐受性良好；在实验期间生命体征和实验室指标未显示出具有临床意义的变化。